<DOC>
	<DOCNO>NCT00220363</DOCNO>
	<brief_summary>The trial consist 2 week Run-In period , 12 week double-blind Treatment period 2 week Safety Follow-Up period . Subjects randomize one 4 treatment arm receive either fesoterodine ( SPM 907 ) 4mg , fesoterodine 8mg , active control ( tolterodine SR 4mg ) placebo Double-Blind Treatment Period . Two primary efficacy variable assess submission United States : change average number micturition ( frequency ) per 24 hour change average number urge incontinence episode per 24 hour . For submission European Union , first primary variable change average number micturition ( frequency ) per 24 hour co-primary variable treatment response , base treatment benefit scale . All continuous variable measure change baseline value 12 week treatment . The important safety variable include assessment adverse event , laboratory parameter , change ECG , physical exam measurement residual urine .</brief_summary>
	<brief_title>A Multicenter Trial Investigate Fesoterodine Sustained Release Overactive Bladder Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Overactive Bladder Syndrome le 8 micturition 24 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>